Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 28, 2014

Sartorius Stedim Biotech Becomes Major Owner of AllPure Technologies

  • Sartorius Stedim Biotech signed a deal to acquire the majority stake in AllPure Technologies. The privately owned, New Oxford, PA-based company specializes in single-use components for biopharmaceutical applications.

    “AllPure further completes our portfolio with innovative products that help our customers develop and manufacture their pharmaceutical drugs safer and more efficiently,” said Reinhard Vogt, member of Sartorius’ executive board.

    “We are excited to leverage Sartorius Stedim’s impressive R&D capabilities so that we can accelerate the launch of new products from AllPure,” added Michael Zumbrum, president of AllPure. And SSB’s global reach and industry relationships grant access to considerably more customers, especially in Europe and Asia, which have tremendous potential for AllPure’s products.

    AllPure’s product portfolio includes the Takeone® aseptic sampling system and the Quickseal® aseptic tube sealing system.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »